ArticleNature communications2021
A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 73 citations in OpenAlex.
- Measurement of the absolute mass concentration of antigen-specific serum IgG via quantitative Western blotting.Analytical biochemistry · 2026Article
- Development of an ELISA Test with High Diagnostic Accuracy for SARS-COV-2 Using Recombinant Nucleocapsid Protein Expressed in E. coli.Molecular biotechnology · 2026Article
- A customizable multiplex protein microarray for antibody testing and its application for tick-borne and other infectious diseases.Scientific reports · 2025Article
- Half-Curcumin-Based Chemiluminescence Probes and Their Applications in Detecting Quasi-Stable Oxidized Proteins.Angewandte Chemie (International ed. in English) · 2024Article
- Review
- Fusing Peptide Epitopes for Advanced Multiplex Serological Testing for SARS-CoV-2 Antibody Detection.ACS bio & med chem Au · 2024Article
- Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.Cell reports methods · 2023Article
- Diagnostics and analysis of SARS-CoV-2: current status, recent advances, challenges and perspectives.Chemical science · 2023Review
- Long-Term Effects of SARS-CoV-2 in the Brain: Clinical Consequences and Molecular Mechanisms.Journal of clinical medicine · 2023Review
- Portable high-throughput multimodal immunoassay platform for rapid on-site COVID-19 diagnostics.Analytica chimica acta · 2023Article
- Incidence of SARS-CoV-2 infection in children shortly after ending zero-COVID-19 policy in China on December 7, 2022: a cross-sectional, multicenter, seroepidemiological study.Frontiers in public health · 2023Article
- Current trends in COVID-19 diagnosis and its new variants in physiological fluids: Surface antigens, antibodies, nucleic acids, and RNA sequencing.Trends in analytical chemistry : TRAC · 2022Review
- An Internet-of-Disease System for COVID-19 Testing Using Saliva by an AI-Controlled Microfluidic ELISA Device.Advanced materials technologies · 2022Article
- Nanoplasmonic multiplex biosensing for COVID-19 vaccines.Biosensors & bioelectronics · 2022Article
- Multiplexed flow cytometric approach for detection of anti-SARS-CoV-2 IgG, IgM and IgA using beads covalently coupled to the nucleocapsid protein.Letters in applied microbiology · 2022Article
- All-solid-state SARS-CoV-2 protein biosensor employing colloidal quantum dots-modified electrode.Biosensors & bioelectronics · 2022Article
- SARS-CoV-2 Antibody Response Is Associated with Age and Body Mass Index in Convalescent Outpatients.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Review
- Multiplex metal-detection based assay (MMDA) for COVID-19 diagnosis and identification of disease severity biomarkers.Chemical science · 2022Article
- Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals.medRxiv : the preprint server for health sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The COVID-19 pandemic affects more than 81 million people worldwide with over 1.7 million deaths. As the population returns to work, it is critical to develop tests that reliably detect SARS-CoV-2-specific antibodies. Here we present results from a multiplex serology test for assessing the antibody responses to COVID-19. In an initial large cohort, this test shows greater than 99% agreement with COVID-19 PCR test. In a second outpatient cohort consisting of adults and children in Colorado, the IgG responses are more robust in positive/symptomatic participants than in positive/asymptomatic participants, the IgM responses in symptomatic participants are transient and largely fall below the detection limit 30 days after symptom onset, and the levels of IgA against SARS-CoV-2 receptor binding domain are significantly increased in participants with moderate-to-severe symptoms compared to those with mild-to-moderate symptoms or asymptomatic individuals. Our results thus provide insight into serology profiling and the immune response to COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.